Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
NCT01707264
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
69
Enrollment
INDUSTRY
Sponsor class
Conditions
Primary Amyloidosis
Interventions
DRUG:
NEOD001
Sponsor
Prothena Biosciences Ltd.